These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12654690)

  • 1. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1447-8. PubMed ID: 12654690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.
    Jones RN; Rhomberg PR
    J Antimicrob Chemother; 2003 Jan; 51(1):157-61. PubMed ID: 12493802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
    Kohlhoff SA; Roblin PM; Reznik T; Hawser S; Islam K; Hammerschlag MR
    Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
    Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
    Chotikanatis K; Kohlhoff SA; Hammerschlag MR
    Antimicrob Agents Chemother; 2014; 58(3):1800-1. PubMed ID: 24366753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.
    Strigl S; Roblin PM; Reznik T; Hammerschlag MR
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1112-3. PubMed ID: 10722526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
    Wise R; Andrews JM; Ashby J
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1117-8. PubMed ID: 11897602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Malay S; Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2002 Feb; 46(2):517-8. PubMed ID: 11796366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
    Kohlhoff SA; Huband MD; Hammerschlag MR
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
    Apfel C; Banner DW; Bur D; Dietz M; Hirata T; Hubschwerlen C; Locher H; Page MG; Pirson W; Rossé G; Specklin JL
    J Med Chem; 2000 Jun; 43(12):2324-31. PubMed ID: 10882358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Hammerschlag MR
    Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.
    Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF
    Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
    Anderegg TR; Biedenbach DJ; Jones RN;
    Int J Antimicrob Agents; 2003 Jul; 22(1):84-6. PubMed ID: 12842335
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1515-6. PubMed ID: 9624507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
    Fritsche TR; Moet GJ; Jones RN
    Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kohlhoff SA; Huerta N; Hammerschlag MR
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antibacterial activity of peptide deformylase inhibitors.
    Huntington KM; Yi T; Wei Y; Pei D
    Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.